tiprankstipranks
Trending News
More News >
Immucell Corp. (ICCC)
NASDAQ:ICCC
Advertisement

Immucell (ICCC) Price & Analysis

Compare
78 Followers

ICCC Stock Chart & Stats


Immucell News

ICCC FAQ

What was Immucell Corp.’s price range in the past 12 months?
Immucell Corp. lowest stock price was $3.34 and its highest was $7.60 in the past 12 months.
    What is Immucell Corp.’s market cap?
    Immucell Corp.’s market cap is $58.98M.
      When is Immucell Corp.’s upcoming earnings report date?
      Immucell Corp.’s upcoming earnings report date is Nov 17, 2025 which is in 71 days.
        How were Immucell Corp.’s earnings last quarter?
        Immucell Corp. released its earnings results on Aug 14, 2025. The company reported $0.056 earnings per share for the quarter, beating the consensus estimate of N/A by $0.056.
          Is Immucell Corp. overvalued?
          According to Wall Street analysts Immucell Corp.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Immucell Corp. pay dividends?
            Immucell Corp. does not currently pay dividends.
            What is Immucell Corp.’s EPS estimate?
            Immucell Corp.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Immucell Corp. have?
            Immucell Corp. has 9,045,851 shares outstanding.
              What happened to Immucell Corp.’s price movement after its last earnings report?
              Immucell Corp. reported an EPS of $0.056 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -9.226%.
                Which hedge fund is a major shareholder of Immucell Corp.?
                Currently, no hedge funds are holding shares in ICCC

                Company Description

                Immucell Corp.

                ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

                Immucell (ICCC) Earnings & Revenues

                ICCC Earnings Call

                Q2 2025
                0:00 / 0:00
                Earnings Call Sentiment|Neutral
                ImmuCell showed strong financial performance with significant sales growth and gross margin improvement, alongside a successful debt refinancing. However, challenges remain with potential sales softening, FDA approval delays for Re-Tain, and the need to regain customer trust after supply issues.View all ICCC earnings summaries
                Similar Stocks
                Company
                Price & Change
                Follow
                Medicinova
                Adicet Bio
                Werewolf Therapeutics
                Telomir Pharmaceuticals, Inc.
                Artiva Biotherapeutics, Inc.

                Ownership Overview

                1.58%3.59%1.45%89.66%
                1.45% Other Institutional Investors
                89.66% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis